

 <p>MaineHealth CANCER CARE NETWORK SUPPORTED BY THE HAROLD ALFOND* FOUNDATION</p>	<i>MaineHealth Thoracic Oncology Specialty Tumor Board Referral Guideline</i>	
	Original Date: 8-16-17	Review Date: 9-4-19
	MHCCN Thoracic Oncology Work Group	

The MHCCN Thoracic Work Group recommends the following five referral guidelines to our multidisciplinary Specialty Tumor Board at MaineGeneral Medical Center or Maine Medical Center:

- 1) All patients with Clinical Stage II disease should be presented at a multidisciplinary tumor board [via telephone, telemedicine (MHCCN Subspecialty eTumor Board) or in person] comprised of medical oncology, radiation oncology, thoracic surgery and pathology to evaluate and discuss options for multi-modality treatment;
- 2) All patients with Clinical Stage III disease should be presented at a multidisciplinary tumor board [via telephone, telemedicine (MHCCN Subspecialty eTumor Board), or in person] to be reviewed/referred, prior to combined and/or sequential multi-modality treatment (i.e., medical oncology, radiation oncology, thoracic surgery or any combination thereof);
- 3) Select Clinical Stage I and Stage IV patients should also be presented at a multidisciplinary tumor board [via telephone, telemedicine (MHCCN Subspecialty eTumor Board) or in person] to review care and options for therapy;
- 4) For all patients with advanced stage disease (i.e., not a candidate for curative intent therapy) referral for palliative care consult is considered current state-of-the art with documentation of plan (including appropriate systemic therapy) and goals of care; and
- 5) For all patients referral and/or participation on clinical trials is to be encouraged.



* *Include select Stage I and Stage IV as appropriate for multidisciplinary review.*

